MedDataX Logo

Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

NCT ID: NCT07244601

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-22

Study Completion Date

2028-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Assess sarcopenia prevalence in elderly diabetic patients.
2. Evaluate impact of diabetes and its medications on muscle health.
3. detect effect of sacropenia on quality of life on elderly

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetic Group

Elderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria.

muscle ultrasound

Intervention Type DIAGNOSTIC_TEST

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Non-Diabetic Group

Elderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria.

muscle ultrasound

Intervention Type DIAGNOSTIC_TEST

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

muscle ultrasound

Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)

●Able to give informed consent

Exclusion Criteria

* chronic renal disease
* chronic liver disese
* Severe cognitive impairment
* Known neuromuscular diseases affecting mobility
* malignancy Data of the study will collected over one year duration from 1/2026 \_1/2027
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eman Alaa Eldean Mohamed

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eman Alaa Eldean Mohamed

house office of Internal Medicine, Assiut University

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

eman alaa eldean, master degree

Role: CONTACT

Phone: 2+01098614329

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884.

Reference Type RESULT
PMID: 34904651 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

sarcopenia in elderly diabetic

Identifier Type: -

Identifier Source: org_study_id